Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03820778 |
Recruitment Status :
Enrolling by invitation
First Posted : January 29, 2019
Last Update Posted : January 29, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Neurofibromatosis 1 Neurofibroma Atypical Neurofibroma Atypical Neurofibromatosis Plexiform Neurofibroma Von Recklinghausen Disease | Diagnostic Test: Whole Body MRI | Not Applicable |
This is a study to determine the feasibility of using Whole Body MRI (WBMRI) to detect Atypical Plexiform Neurofibromas (ANF) among Neurofibromatosis Type 1 (NF1) patients who are at highest risk for developing these tumors. In order to do this, the investigators will prospectively obtain WBMRI scans on patients with high plexiform tumor burden (which investigators will define as >=1 plexiform neurofibroma (PN) that is >3cm in diameter on MRI) at the same time as their regularly scheduled MRI to allow for radiographic comparison of the identified PNs. In this study, the investigators will plan to establish a method that effectively characterizes PNs in terms of their volume, radiographic appearance on WBMRI and association with clinical characteristics.
As an exploratory aim, the investigators plan to collect blood samples from each patient at the same time as the MRI to determine the feasibility of isolating cfDNA (circulating free DNA) from plasma of patients with high plexiform tumor burden.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 and High Plexiform Neurofibroma Tumor Burden |
Actual Study Start Date : | July 12, 2018 |
Estimated Primary Completion Date : | July 12, 2022 |
Estimated Study Completion Date : | July 12, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Study Arm
Whole Body MRI along with standard of care regional MRI and blood draw at enrollment followed by Whole Body MRI along with standard of care regional MRI and blood draw after 4-6 months.
|
Diagnostic Test: Whole Body MRI
WBMRI with axial and coronal STIR (short inversion time inversion recovery) images + DWI (diffuse weighted imaging) will be performed and compared to regional MRI to assess value of this diagnostic test for the identification of suspicious looking lesions (i.e. diffuse nodular lesions or atypical plexiform neurofibroma) |
- To determine if WBMRI can be used to identify ANF in NF1 patients with high tumor burden. [ Time Frame: 2-3 years ]We will review results of the WBMRI compared to regional MRIs (done with contrast) to determine if the WBMRI can accurately detect Atypical Neurofibromas.
- Determine if clinical signs and symptoms correlate with tumor burden and/or the presence of ANF on WBMRI [ Time Frame: 2-3 years ]Using patient data collected during their routine clinic evaluation, we will determine if clinical signs and symptoms correlate with tumor burden and/or the presence of ANF on WBMRI
- Determine if the cfDNA levels correlate with presence of ANF. [ Time Frame: 3-4 years ]We will measure cfDNA levels in each participant, and determine if these levels correlate with tumor burden and/or the presence of ANFs.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 8 Years to 30 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males or females between 8-30 years of age
- Confirmed diagnosis of NF1
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Prior MRI documentation confirming >=1 PN that is >3cm in diameter
Exclusion Criteria:
- Unable to undergo MRI without sedation
- Presence of metal or other devices that are contraindicated for MRI

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03820778
United States, District of Columbia | |
Children's National Health System | |
Washington, District of Columbia, United States, 20010 |
Principal Investigator: | Miriam Bornhorst, MD | Children's National Health System |
Responsible Party: | Miriam Bornhorst, Assistant Professor Division of Oncology and Center for Genetics Medicine, Children's National Research Institute |
ClinicalTrials.gov Identifier: | NCT03820778 |
Other Study ID Numbers: |
Pro00010431 |
First Posted: | January 29, 2019 Key Record Dates |
Last Update Posted: | January 29, 2019 |
Last Verified: | January 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
Neurofibromatoses Neurofibromatosis 1 Neurofibroma Neurofibroma, Plexiform Nerve Sheath Neoplasms Neoplasms, Nerve Tissue Neoplasms by Histologic Type Neoplasms Neoplastic Syndromes, Hereditary |
Neurocutaneous Syndromes Nervous System Diseases Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn Peripheral Nervous System Diseases Neuromuscular Diseases Peripheral Nervous System Neoplasms Nervous System Neoplasms |